This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2021 Feb 18;137(7):867-868.

doi: 10.1182/blood.2020008876.

BiTtEn by Src inhibitors

Philippe Rousselot¹

Affiliations

PMID: 33599758
DOI: 10.1182/blood.2020008876

Free article

Editorial

BiTtEn by Src inhibitors

Philippe Rousselot. Blood. 2021.

Free article

. 2021 Feb 18;137(7):867-868.

doi: 10.1182/blood.2020008876.

Author

Philippe Rousselot¹

Affiliation

¹ Centre Hospitalier de Versailles; Université Versailles Saint-Quentin-en-Yvelines et Paris-Saclay; UMR1184.

PMID: 33599758
DOI: 10.1182/blood.2020008876

No abstract available

PubMed Disclaimer

Comment on

Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL.
Leonard JT, Kosaka Y, Malla P, LaTocha D, Lamble A, Hayes-Lattin B, Byrd K, Druker BJ, Tyner JW, Chang BH, Lind E. Leonard JT, et al. Blood. 2021 Feb 18;137(7):939-944. doi: 10.1182/blood.2020005655. Blood. 2021. PMID: 32898857 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems
Other Literature Sources
- scite Smart Citations
Miscellaneous
- NCI CPTAC Assay Portal